Home › Atrial Fibrillation › NCT05643235

Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

Implanted Loop Recorders (ILR) for the Detection and Management of Arrhythmia in Patients Treated With Bruton Tyrosine Kinase (BTK) Inhibitors

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* \>18yo
* Willing to sign and date consent form,
* Willing to be remotely monitored
* Initiating BTK inhibitor for approved condition (i.e. CLL, Waldenstrom's, etc)
* Willing to have Medtronic cardiac monitor inserted to allow at minimum 24 hours continuous monitoring prior to initiating BTK inhibitor

Exclusion Criteria:

* Documented AF/VA in past 12 months
* Cerebral Vascular Accident (CVA) or Transient Ischemic Attack (TIA) in past year
* Has current implanted pulse generator, defibrillator, pacemaker, or resynchronization device
* heart surgery within past 90 days
* Myocardial Infarction within past 90 days
* Patient is taking an anti-arrhythmic or anticoagulant
* has concomitant condition that precludes safe participation in study (substance abuse, etc)
* Enrollment in separate study that could confound results of this study

About the study

This study will enroll patients initiating Bruton Tyrosine Kinase (BTK) inhibitors without history of documented arrhythmia while on therapy using the Medtronic LINQ-2 insertable cardiac monitor (ILR). The incidence of new onset atrial fibrillation (AF) and other arrhythmia will be determined. Actions taken in response to device detected arrhythmia will be recorded.

What is being tested

• Medtronic LINQ-2 Insertable Cardiac Monitor (ILR) (device)

Sponsor: Northwell Health · Participants: 50 · Started: Jan 1, 2023

Contact the study team

• Efstathia Mihelis · Phone: 212-434-6614
• Robert S Copeland-Halperin, MD · Phone: 718-470-7330

Official record on ClinicalTrials.gov — NCT05643235

Locations in the U.S.

Conditions

• Atrial Fibrillation
• Sudden Cardiac Arrest
• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma
• Waldenstrom Macroglobulinemia
• Cardiac Sudden Death

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.